- Arcutis Biotherapeutics ( NASDAQ: ARQT ) said it launched its plaque psoriasis cream Zoryve in the U.S.
- In July, the U.S. FDA approved Zoryve (roflumilast) cream 0.3% for topical use to treat plaque psoriasis in people aged 12 years and older.
- The company said the product was available via ZORYVE Direct pharmacies — contracted pharmacy partners that help commercially insured individuals get access to the drug — and will be available for ordering at pharmacies nationwide no later than Aug. 15.
For further details see:
Arcutis launches plaque psoriasis therapy Zoryve in US